Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 911 to 920 of 2733 total matches.

Empagliflozin (Jardiance) for Heart Failure

   
The Medical Letter on Drugs and Therapeutics • Nov 16, 2020  (Issue 1611)
diabetes.1 To date, empagliflozin has not been approved by the FDA for such use. The SGLT2 inhibitor ...
In a randomized, placebo-controlled trial, the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance – Boehringer Ingelheim/Lilly) reduced the composite risk of cardiovascular death or hospitalization for worsening heart failure (HF) in patients with heart failure with reduced ejection fraction (HFrEF), whether or not they had type 2 diabetes. To date, empagliflozin has not been approved by the FDA for such use. The SGLT2 inhibitor dapagliflozin (Farxiga) was approved by the FDA for this indication earlier this year.
Med Lett Drugs Ther. 2020 Nov 16;62(1611):177-8 |  Show IntroductionHide Introduction

Teprotumumab (Tepezza) for Thyroid Eye Disease

   
The Medical Letter on Drugs and Therapeutics • May 31, 2021  (Issue 1625)
-like growth factor-1 receptor (IGF-1R) inhibitor, has been approved by the FDA for IV treatment ...
Teprotumumab-trbw (Tepezza - Horizon), an insulin-like growth factor-1 receptor (IGF-1R) inhibitor, has been approved by the FDA for IV treatment of thyroid eye disease. It is the first drug to be approved in the US for this indication.
Med Lett Drugs Ther. 2021 May 31;63(1625):87-8 |  Show IntroductionHide Introduction

Amivantamab (Rybrevant) for Non-Small Cell Lung Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022  (Issue 1663)
an overall response; the median duration of response was 11.1. months. ▶ Adverse Effects: Infusion-related ...
Amivantamab-vmjw (Rybrevant – Janssen), an EGFR-MET bispecific antibody, has received accelerated approval from the FDA for IV treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations in adults whose disease has progressed on or after platinum-based chemotherapy. It is the first bispecific antibody to become available in the US for this indication. Accelerated approval of the drug was based on the overall response rate and duration of response.
Med Lett Drugs Ther. 2022 Nov 14;64(1663):e184-5 |  Show IntroductionHide Introduction

Delandistrogene Moxeparvovec (Elevidys) for Duchenne Muscular Dystrophy

   
The Medical Letter on Drugs and Therapeutics • Oct 02, 2023  (Issue 1686)
, recessive, progressive neuromuscular disorder (estimated prevalence 1:5000 live male births) characterized ...
Delandistrogene moxeparvovec-rokl (Elevidys – Sarepta), an adeno-associated virus (AAV) vector-based gene therapy, has received accelerated approval from the FDA for treatment of ambulatory children 4-5 years old with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the dystrophin gene. It is the first gene therapy to be approved in the US for treatment of DMD. Accelerated approval was based on expression of microdystrophin in skeletal muscle, a surrogate endpoint.
Med Lett Drugs Ther. 2023 Oct 2;65(1686):159-60   doi:10.58347/tml.2023.1686d |  Show IntroductionHide Introduction

In Brief: Adjunctive Pramipexole for Treatment-Resistant Depression

   
The Medical Letter on Drugs and Therapeutics • Oct 13, 2025  (Issue 1739)
with treatment-resistant depression (TRD).1 A double-blind, placebo-controlled trial of pramipexole augmentation ...
The oral nonergot dopamine agonist pramipexole (Mirapex ER, and generics), which is FDA-approved for treatment of Parkinson's disease and restless legs syndrome, has been used off-label in patients with treatment-resistant depression (TRD). A double-blind, placebo-controlled trial of pramipexole augmentation in patients with unipolar TRD was recently published.
Med Lett Drugs Ther. 2025 Oct 13;67(1739):165-6   doi:10.58347/tml.2025.1739c |  Show IntroductionHide Introduction

In Brief: Updates for Lecanemab (Leqembi) for Alzheimer's Disease

   
The Medical Letter on Drugs and Therapeutics • Nov 10, 2025  (Issue 1741)
with the amyloid betadirected monoclonal antibody lecanemab-irmb (Leqembi)1 and has approved a new subcutaneously ...
The FDA has recommended additional MRI monitoring during initiation of treatment with the amyloid beta-directed monoclonal antibody lecanemab-irmb (Leqembi) and has approved a new subcutaneously injected formulation of the drug (Leqembi Iqlik) for maintenance treatment of Alzheimer's disease.
Med Lett Drugs Ther. 2025 Nov 10;67(1741):182-3   doi:10.58347/tml.2025.1741d |  Show IntroductionHide Introduction

Drugs for Asthma

   
The Medical Letter on Drugs and Therapeutics • Nov 25, 2024  (Issue 1716)
, prevent exacerbations, and maintain normal lung function.1,2 Management of acute exacerbations ...
The goal of asthma treatment is to control symptoms, prevent exacerbations, and maintain normal lung function. Management of acute exacerbations in the emergency department is not discussed here.
Med Lett Drugs Ther. 2024 Nov 25;66(1716):185-92   doi:10.58347/tml.2024.1716a |  Show IntroductionHide Introduction

In Brief: One Drop or Two

   
The Medical Letter on Drugs and Therapeutics • Jun 19, 2006  (Issue 1237)
Publication One Drop or Two? IN BRIEF Many prescriptions for eye drops call for instillation of 1-2 drops ...
Many prescriptions for eye drops call for instillation of 1-2 drops. But Medical Letter consultants in ophthalmology seem to agree that all eye drops should generally be given in doses of only one drop. The volume of a single drop can vary with the viscosity of the solution, the design of the dropper, and patient technique. The average volume of a drop is 35-50 microliters, but can be as high as 75 microliters. An eye brimming with fluid holds 30 microliters at best, so even one drop is often an overdose. A second either washes out the first or increases the possibility of systemic toxicity,...
Med Lett Drugs Ther. 2006 Jun 19;48(1237):49 |  Show IntroductionHide Introduction

Transdermal Rotigotine (Neupro) for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Aug 27, 2007  (Issue 1268)
each day. 1 Pergolide (Permax, and others), an ergot-derived dopamine agonist used for many years ...
Rotigotine (Neupro - Schwarz Pharma), a nonergot dopamine agonist in a transdermal patch formulation, was recently approved by the FDA for treatment of early Parkinson's disease (PD).
Med Lett Drugs Ther. 2007 Aug 27;49(1268):69-70 |  Show IntroductionHide Introduction

Tetramune - A Combined Vaccine For Infants

   
The Medical Letter on Drugs and Therapeutics • Nov 12, 1993  (Issue 909)
RECOMMENDED VACCINATIONS FOR INFANTS Schedule (Months of Age) Vaccine 2 4 6 15 Cost 1 DTP DTP (Connaught ...
The number of immunizations recommended for infants and young children has increased in recent years with the addition of vaccines to prevent Haemophilus influenzae type b infection and hepatitis B (Medical Letter, 33:5, 1991; 34:69, 1992). Now the US Food and Drug Administration has licensed a new vaccine for infants (Tetramune - Lederle-Praxis) that combines a traditional diphtheria, tetanus, and pertussis vaccine (DTP; Tri-Immunol) with a vaccine against Haemophilus influenzae type b (HibTiter).
Med Lett Drugs Ther. 1993 Nov 12;35(909):104-5 |  Show IntroductionHide Introduction